NewsEvents

Your Yourlocation: Home > Tiotropium bromide(136310-93-5) continued to improve lung function during the two-year period

The Tie-COPD study (COPD Early Drug Intervention Study), which was conducted by 24 hospitals (communities), including the Guangzhou Medical University Hospital, the Guangzhou Respiratory Disease Research Institute and the State Key Laboratory of Respiratory Diseases, was conducted on Chinese patients with early COPD. Observed by community screening of patients selected, the study selected tiotropium bromide(136310-93-5) as an observation drug, placebo as a control group to observe changes in lung function during the two-year treatment, the main observation of the two-year decline in lung function treatment rate, Safety, quality of life were also recorded.

The results showed that tiotropium bromide(136310-93-5) continued to improve lung function in patients during the two-year period, while quality-of-life scores improved and risk of COPD acute exacerbation (AECOPD) was lower with safety comparable to placebo. The clinical implication of this study is that tiotropium bromide(136310-93-5) improves lung function more significantly in patients with early COPD than in the later stages of the study, the study confirms for the first time that even in asymptomatic patients with COPD, pulmonary function is evident after 2 years of treatment improve. The rate of decline in FEV1 after treatment in patients with COPDI-II has also improved and is approaching normal. Therefore, this study suggests that upstream (early) treatment strategies for COPD may be more reversible.


Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved